Pirfenidone now included
Posted in News
Historically, preparations of pirfenidone (Esbriet®) have been excluded from mapped drugs due to a commercial sensitivity issue with the original patent holder. Now the current license holder and the Patient Access Scheme Liaison Unit (PASLU) have confirmed that this confidentiality agreement is no longer applicable and so we mapped all pirfenidone preparations to dm+d in early January.
Importantly, this virtual medicinal product (VMP) is now included in a number of Tags so individual drug lines from Trusts will be identifiable. Tags affected include those for NICE Technology Appraisal TA282 and NICE All Drugs, High Cost Drugs List 2017-19, Patient Access Scheme List, Non-PbR and Passthrough Costs (current). The list of tags can be viewed here.
The only therapeutic moiety that remains unmapped across all of the dm+d concept is Ivacaftor®. This is being reviewed by the NHS at present.